Filing Details

Accession Number:
0000899243-20-023547
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-27 19:26:40
Reporting Period:
2020-08-25
Accepted Time:
2020-08-27 19:26:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1802665 Harmony Biosciences Holdings Inc. HRMY () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1602402 Jack Nielsen C/o 630 W. Germantown Pike, Suite 215
Plymouth Meeting PA 19462
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-25 823 $34.20 38,780 No 4 P Indirect See Footnote
Common Stock Acquisiton 2020-08-26 3,922 $34.30 42,702 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Footnotes
  1. The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.
  2. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $33.3 to $34.8, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $33.9 to $35.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.